Natera CEO Explains What The Company Does And Why It's Not Focused On 'To Keep Growing Revenues'

Genetic testing company Natera Inc NTRA had a successful debut on the NASDAQ on Thursday. The company opened for trade at $22.60, significantly above its IPO price of $18 and continues to trade above that mark.

Matthew Rabinowitz, Chairman, CEO and co-founder of Natera was on CNBC post the stock's debut to discuss what the company does and share his outlook for the business going forward.

Focussing On World Not On Revenues

"Our goal is not to keep growing revenues, but to make the world a better place," Rabinowitz began. "And, I think, if you focus on the kind of testing that we do to improve healthcare decisions and improve healthcare outcomes, I think, the revenue will follow. So, we don't focus on the revenue, we focus on the world and, I think, with that focus the revenue will keep coming."

Improving Healthcare Decisions

Rabinowitz was asked to explain what exactly does Natera does and how its helping in improving genetic testing. He replied, "Well, Natera has taken a set of communications technologies that are used in things like our cell phones and spaceships and we have applied that to looking at tiny [amounts] of DNA to improve genetic testing."

"So, the [idea] is being able to detect single molecules of DNA sometimes. We can catch genetic diseases like Down's syndrome and breast cancer earlier and more easily. So, that improves healthcare decisions. And by catching cancers for example earlier, our goal is to improve survival rates," Rabinowitz concluded.